Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Expected to Rise, Maxim Group Analyst Says

Chemomab Therapeutics (NASDAQ:CMMB) had its price target boosted by analysts at Maxim Group from $4.00 to $7.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 309.36% from the stock’s current price.

Separately, Oppenheimer reissued an “outperform” rating and issued a $11.00 price objective (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Trading Down 3.4 %

Shares of CMMB opened at $1.71 on Thursday. The firm has a fifty day moving average price of $1.97 and a 200-day moving average price of $1.71. The firm has a market capitalization of $24.55 million, a P/E ratio of -1.71 and a beta of 0.66. Chemomab Therapeutics has a 12-month low of $0.58 and a 12-month high of $2.55.

Hedge Funds Weigh In On Chemomab Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CMMB. Virtu Financial LLC purchased a new stake in Chemomab Therapeutics in the fourth quarter worth about $26,000. XTX Topco Ltd raised its holdings in shares of Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Chemomab Therapeutics in the 3rd quarter worth approximately $1,907,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).